Article (Scientific journals)
Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma.
Isci, Damla; D'Uonnolo, Giulia; Wantz, May et al.
2021In Cancers, 14 (1), p. 130
Peer Reviewed verified by ORBi
 

Files


Full Text
cancers-14-00130.pdf
Author postprint (1.77 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
chemokine receptor; glioma; malignant processes; patient-derived transcriptomic data; tumor microenvironment; Oncology; Cancer Research
Abstract :
[en] Gliomas are severe brain malignancies, with glioblastoma (GBM) being the most aggressive one. Despite continuous efforts for improvement of existing therapies, overall survival remains poor. Over the last years, the implication of chemokines and their receptors in GBM development and progression has become more evident. Recently, large amounts of clinical data have been made available, prompting us to investigate chemokine receptors in GBM from a still-unexplored patient-oriented perspective. This study aims to highlight and discuss the involvement of chemokine receptors-CCR1, CCR5, CCR6, CCR10, CX3CR1, CXCR2, CXCR4, ACKR1, ACKR2, and ACKR3-most abundantly expressed in glioma patients based on the analysis of publicly available clinical datasets. Given the strong intratumoral heterogeneity characterizing gliomas and especially GBM, receptor expression was investigated by glioma molecular groups, by brain region distribution, emphasizing tissue-specific receptor functions, and by cell type enrichment. Our study constitutes a clinically relevant and patient-oriented guide that recapitulates the expression profile and the complex roles of chemokine receptors within the highly diversified glioma landscape. Additionally, it strengthens the importance of patient-derived material for development and precise amelioration of chemokine receptor-targeting therapies.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Isci, Damla   ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
D'Uonnolo, Giulia  ;  Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg ; Faculty of Science, Technology and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg
Wantz, May;  Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg
Rogister, Bernard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
LOMBARD, Arnaud  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie
Chevigné, Andy  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg
Szpakowska, Martyna ;  Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 1445 Strassen, Luxembourg ; Tumor Immunotherapy and Microenvironment, Department of Oncology, Luxembourg Institute of Health, 1445 Strassen, Luxembourg
Neirinckx, Virginie ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
 These authors have contributed equally to this work.
Language :
English
Title :
Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma.
Publication date :
28 December 2021
Journal title :
Cancers
eISSN :
2072-6694
Publisher :
MDPI, Switzerland
Volume :
14
Issue :
1
Pages :
130
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Funding text :
This work was supported by the University of Li?ge, and the Fonds L?on Fr?d?ricq Association, Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (INTER/FNRS grants 20/15084569, and PRIDE 11012546 ?NextImmune? and 14254520 ?I2TRON?), F.R.S.-FNRS-T?l?vie (grants 7.4593.19, 7.4529.19 and 7.8504.20). MS and AC are part of the Marie Sk?odowska-Curie Innovative Training Networks ONCORNET2.0 ?ONCOgenic Receptor Network of Excellence and Training? (MSCA-ITN-2020-ETN).Funding: This work was supported by the University of Liège, and the Fonds Léon Frédéricq Association, Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (INTER/FNRS grants 20/15084569, and PRIDE 11012546 “NextImmune” and 14254520 “I2TRON”), F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). MS and AC are part of the Marie Skłodowska-Curie Innovative Training Networks ONCORNET2.0 “ONCOgenic Receptor Network of Excellence and Training” (MSCA-ITN-2020-ETN).
Available on ORBi :
since 25 February 2022

Statistics


Number of views
170 (15 by ULiège)
Number of downloads
128 (8 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
4
OpenCitations
 
3

Bibliography


Similar publications



Contact ORBi